HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
NCT ID: NCT01484171
Last Updated: 2016-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
50 participants
INTERVENTIONAL
2011-08-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microtransplantation in Older Patients With Acute Myeloid Leukemia
NCT02831192
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
NCT02461121
Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia
NCT02171117
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244
Hematopoietic Stem Cell Microtransplantation for in AML
NCT02676856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
idarubicin
The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
idarubicin
idarubicin 10-12 mg/m2 for three days
microtransplantation
The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
microtransplantation
idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
idarubicin
idarubicin 10-12 mg/m2 for three days
microtransplantation
idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis was based on the French-American-British (FAB) and WHO criteria.
3. Age ≥ 7 years old
4. Age \< 60 years old
Exclusion Criteria
7 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
huisheng ai, M.D.
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Hospital of the Chinese Academy of Military Medical Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Affiliated Hospital of the Chinese Academy of Military Medical Science
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MST-AML-307PLAH-ASH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.